FIELD: chemistry.
SUBSTANCE: invention relates to novel derivative of purinylpyridinylamino-2,4-difluorophenylsulphonamide of formula 1 and its pharmaceutically acceptable salt. Compounds have properties of inhibiting Raf-kinase super activity and can be applied for prevention and treatment of diseases, mediated by activity of Raf-kinase, such as cancer, in particular melanoma. In formula 1 R stands for methyl; ethyl; propyl; isopropyl, butyl, isobutyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; C5-C6aryl, unsubstituted or substituted with one or more substituents, selected from the group, which consists of chlorine, fluorine, bromine, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, trifluoromethoxy, fluoromethoxy, difluorimethoxy and trifluoroethoxy; C5-C12heteroaryl, which consists of one or two rings, non-substituted or substituted with one or more substituents, selected from the group, which consists of chlorine, fluorine, bromine, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, tret- butoxycarbonyl and dioxolanyl; C5-C6heterocycloalkyl, non-substituted or substituted with one or more substituents, selected from the group, which consists of chlorine, fluorine, bromine, methyl, ethyl, propyl, isopropyl, butyl, isobutyl; or C5-C6aryl-linear or branched C1-C6alkyl, non-substituted or substituted with one or more substituents, selected from the group, which consists of chlorine, fluorine, bromine, nitro, methyl, ethyl, propyl, isopropyl, butyl and isobutyl, and heteroaryl and heterocycloalkyl contain in ring one or more heteroatoms, selected from the group, which consists of N, O and S. Invention also relates to methods of obtaining formula 1 compounds.
EFFECT: improvement of characteristics.
15 cl, 3 tbl, 51 ex 1 dwg
Title | Year | Author | Number |
---|---|---|---|
MKK4 PROTEIN KINASE INHIBITORS FOR STIMULATION OF LIVER REGENERATION OR REDUCTION OR PREVENTION OF HEPATOCYTE DEATH | 2019 |
|
RU2788000C2 |
AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS MEDICINE | 2012 |
|
RU2600976C2 |
AZABICYCLO-QUINOLONE CAROBOXYLIC ACIDS OR THEIR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE SALTS AND INTERMEDIATE PRODUCTS FOR THEIR SYNTHESIS | 1989 |
|
RU2049777C1 |
THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | 2012 |
|
RU2606497C2 |
GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE INGREDIENT | 2008 |
|
RU2450001C2 |
AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
DERIVATIVES OF AZAINDASOLE OR DIAZAINDASOLE TYPE FOR PAIN TREATMENT | 2013 |
|
RU2640046C2 |
ISOQUINOLINONE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH POLY(ADP-ribose)POLYMERASE-1, CONTAINING THEM AS ACTIVE INGREDIENT | 2020 |
|
RU2815480C1 |
PROTEIN KINASE INHIBITORS FOR ENHANCING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | 2019 |
|
RU2822216C2 |
HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2710743C2 |
Authors
Dates
2015-05-10—Published
2011-11-25—Filed